Limitations in Survival
ECM barriers formed by CAFs and immune-suppressive signals restrict vascular and immune cell infiltration.
Targeting CAFs
Cancer-associated fibroblasts (CAFs) remodel the ECM surrounding tumors, continuously promoting tumor growth and metastasis.
Penetrium™
Selectively eliminates CAFs to improve the tumor microenvironment and overcome pseudo-resistance.
Cancer Type | Metastasis Rate | Median Overall Survival After Metastasis (Median OS) | Histological Image |
Lung Cancer | ~40–55% (at diagnosis) | ~7–15 months (NSCLC) |  |
Breast Cancer | ~20–30% (progression during disease course) | ≤15 months (TNBC) |  |
Prostate Cancer | ~10–20% (4–10% at diagnosis, including progression) | ≤12 months (CRPC) |  |
Pancreatic Cancer | ~50–60% (at diagnosis) | ~6–11 months |  Normal Pancreas  Pancreatic Cancer |
Cancer Type | Metastasis Rate | Median Overall Survival After Metastasis (Median OS) | Histological Image |
Lung Cancer | ~40–55% (at diagnosis) | ~7–15 months (NSCLC) | |
Breast Cancer | ~20–30% (progression during disease course) | ≤15 months (TNBC) | |
Prostate Cancer | ~10–20% (4–10% at diagnosis, including progression) | ≤12 months (CRPC) | |
Pancreatic Cancer | ~50–60% (at diagnosis) | ~6–11 months | Normal Pancreas Pancreatic Cancer |
